scholarly journals Pericytes contribute to airway remodeling in a mouse model of chronic allergic asthma

2015 ◽  
Vol 308 (7) ◽  
pp. L658-L671 ◽  
Author(s):  
Jill R. Johnson ◽  
Erika Folestad ◽  
Jessica E. Rowley ◽  
Elisa M. Noll ◽  
Simone A. Walker ◽  
...  

Myofibroblast accumulation, subepithelial fibrosis, and vascular remodeling are complicating features of chronic asthma, but the mechanisms are not clear. Platelet-derived growth factors (PDGFs) regulate the fate and function of various mesenchymal cells and have been implicated as mediators of lung fibrosis. However, it is not known whether PDGF-BB signaling via PDGFRβ, which is critical for the recruitment of pericytes to blood vessels, plays a role in airway remodeling in chronic asthma. In the present study, we used a selective PDGFRβ inhibitor (CP-673451) to investigate the role of PDGFRβ signaling in the development of airway remodeling and lung dysfunction in an established mouse model of house dust mite-induced chronic allergic asthma. Unexpectedly, we found that pharmacological inhibition of PDGFRβ signaling in the context of chronic aeroallergen exposure led to exacerbated lung dysfunction and airway smooth muscle thickening. Further studies revealed that the inflammatory response to aeroallergen challenge in mice was associated with decreased PDGF-BB expression and the loss of pericytes from the airway microvasculature. In parallel, cells positive for pericyte markers accumulated in the subepithelial region of chronically inflamed airways. This process was exacerbated in animals treated with CP-673451. The results indicate that perturbed PDGF-BB/PDGFRβ signaling and pericyte accumulation in the airway wall may contribute to airway remodeling in chronic allergic asthma.

2019 ◽  
Vol 189 (4) ◽  
pp. 762-772 ◽  
Author(s):  
Nazanin Tatari ◽  
Hesam Movassagh ◽  
Lianyu Shan ◽  
Latifa Koussih ◽  
Abdelilah S. Gounni

2018 ◽  
Vol 47 (2) ◽  
pp. 579-589 ◽  
Author(s):  
Wei Li ◽  
Yaojun Lu ◽  
Ruijuan Han ◽  
Qiang Yue ◽  
Xiurong Song ◽  
...  

Background/Aims: The transplantation of cardiac progenitor cells (CPCs) improves neovascularization and left ventricular function after myocardial infarction (MI). The bone morphogenetic protein antagonist Gremlin 2 (Grem2) is required for early cardiac development and cardiomyocyte differentiation. The present study examined the role of Grem2 in CPC differentiation and cardiac repair. Methods: To determine the role of Grem 2 during CPC differentiation, c-Kit+ CPCs were cultured in differentiation medium for different times, and Grem2, Notch1 and Jagged1 expression was determined by RT-PCR and western blotting. Short hairpin RNA was used to silence Grem2 expression, and the expression of cardiomyocyte surface markers was assessed by RT-PCR and immunofluorescence staining. In vivo experiments were performed in a mouse model of left anterior descending coronary artery ligation-induced MI. Results: CPC differentiation upregulated Grem2 expression and activated the Notch1 pathway. Grem2 knockdown inhibited cardiomyocyte differentiation, and this effect was similar to that of Notch1 pathway inhibition in vitro. Jagged1 overexpression rescued the effects of Grem2 silencing. In vivo, Grem2 silencing abolished the protective effects of CPC injection on cardiac fibrosis and function. Conclusions: Grem2 regulates CPC cardiac differentiation by modulating Notch1 signaling. Grem2 enhances the protective effect of CPCs on heart function in a mouse model of MI, suggesting its potential as the rapeutic protein for cardiac repair.


CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 812S
Author(s):  
Jin Woo Kim ◽  
Young Hyeun Kim ◽  
Sang Haak Lee ◽  
Seung Joon Kim ◽  
Young-Kyoon Kim ◽  
...  

2002 ◽  
Vol 32 (7) ◽  
pp. 1104-1111 ◽  
Author(s):  
R. K. Kumar ◽  
C. Herbert ◽  
M. Yang ◽  
A. M. L. Koskinen ◽  
A. N. J. McKenzie ◽  
...  

2015 ◽  
Vol 308 (2) ◽  
pp. L191-L198 ◽  
Author(s):  
Felix Nau ◽  
Justin Miller ◽  
Jordy Saravia ◽  
Terry Ahlert ◽  
Bangning Yu ◽  
...  

Asthma is an inflammatory disease of the lung characterized by airways hyper-responsiveness (AHR), inflammation, and mucus hyperproduction. Current mainstream therapies include bronchodilators that relieve bronchoconstriction and inhaled glucocorticoids to reduce inflammation. The small molecule hormone and neurotransmitter serotonin has long been known to be involved in inflammatory processes; however, its precise role in asthma is unknown. We have previously established that activation of serotonin 5-hydroxytryptamine (5-HT)2Areceptors has potent anti-inflammatory activity in primary cultures of vascular tissues and in the whole animal in vasculature and gut tissues. The 5-HT2Areceptor agonist, ( R)-2,5-dimethoxy-4-iodoamphetamine [( R)-DOI] is especially potent. In this work, we have examined the effect of ( R)-DOI in an established mouse model of allergic asthma. In the ovalbumin mouse model of allergic inflammation, we demonstrate that inhalation of ( R)-DOI prevents the development of many key features of allergic asthma, including AHR, mucus hyperproduction, airways inflammation, and pulmonary eosinophil recruitment. Our results highlight a likely role of the 5-HT2receptors in allergic airways disease and suggest that 5-HT2receptor agonists may represent an effective and novel small molecule-based therapy for asthma.


PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e51268 ◽  
Author(s):  
Zhuang-Gui Chen ◽  
Tian-Tuo Zhang ◽  
Hong-Tao Li ◽  
Fen-Hua Chen ◽  
Xiao-Ling Zou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document